Abstract:Advanced ovarian cancer is a devastating disease. Gaining biomarkers of early detection during ovarian tumorigenesis may lead to earlier diagnosis and better therapeutic strategies. Cystatin B (CSTB) functions as an inhibitor to suppress intracellular cysteine proteases and has been implicated in several types of cancers. The present study explored the expression of CSTB in human ovarian tumors, to investigate CSTB expression associated with clinicopathological features, and to examine the effect of transforming growth factor-β (TGF-β), which plays a key role in ovarian tumorigenesis, on CSTB expression in ovarian cancer cells. The ovarian tissue samples from 33 patients were retrieved. The expression of CSTB in ovarian tissue was examined by immunohistochemistry. We found that CSTB was over-expressed in human ovarian surface epithelial tumors, including serous, mucinous and clear cell tumors. The immunoreactive staining of CSTB was strong in borderline and malignant tumors, weak in benign tumors, and negative in normal tissue counterparts, but was not correlated with the clinicopathological features of patients with ovarian tumors, such as age, histological types, tumor size, lymph node metastasis and clinical stages. The CSTB at mRNA and protein levels in two types of epithelial ovarian cancer cells, OVCAR-3 and SK-OV-3, was decreased after TGF-β1 treatment detected by quantitative PCR and western blot analysis, respectively. The inhibitory effect of TGF-β1 on CSTB expression was abolished in the presence of SB-431542, a TGF-β type I receptor kinase inhibitor. Our data suggest that CSTB is tumor tissue-specific and overexpressed in ovarian borderline and malignant tumors. The increased CSTB expression in ovarian tissue represents tumor progression and is dysregulated by the TGF-β signaling pathway. CSTB may become a novel diagnostic intracellular biomarker for the early detection of ovarian cancer.

Cathepsin B and Its Interacting Proteins, Bikunin and TSRC1, Correlate with TNF-induced Apoptosis of Ovarian Cancer Cells OV-90.

Human Homologue of Seta Binding Protein 1 Interacts with Cathepsin B and Participates in TNF-Induced Apoptosis in Ovarian Cancer Cells

Acetyl-Coenzyme A acyltransferase 2 attenuates the apoptotic effects of BNIP3 in two human cell lines.

Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors

Mendelian randomization analysis to explore the relationship between cathepsins and malignant ovarian tumors

Bik/NBK Accumulation Correlates with Apoptosis-Induction by Bortezomib (PS-341, Velcade) and Other Proteasome Inhibitors

Influence of Apoptin on Up-Regulation of the Expression of Bad and Bax

Inhibition of cathepsin K sensitizes oxaliplatin-induced apoptotic cell death by Bax upregulation through OTUB1-mediated p53 stabilization in vitro and in vivo

Experimental Study on Apoptosis in T Cells Induced by Ovarian Carcinoma Cells

HSP60-regulated Mitochondrial Proteostasis and Protein Translation Promote Tumor Growth of Ovarian Cancer

Cathepsin B Regulates Mice Granulosa Cells’ Apoptosis and Proliferation In Vitro

Intrinsically Connected: Therapeutically Targeting the Cathepsin Proteases and the Bcl-2 Family of Protein Substrates as Co-regulators of Apoptosis

Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF-β signaling pathway

Cysteine proteinases in tumor cell growth and apoptosis

Silencing of Cathepsin B Suppresses the Proliferation and Invasion of Endometrial Cancer

Increased expression of Cathepsin B in oral squamous cell carcinoma.

Cathepsin B in programmed cell death machinery: mechanisms of execution and regulatory pathways

Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.

Cathepsin B may be a potential biomarker in cervical cancer.

Cucurbitacin I induces apoptosis in ovarian cancer cells through oxidative stress and the p190B‐Rac1 signaling axis

Apoptosis of Human Prostate Cancer PC-3 Cells is Mediated by Lysosomal Cathepsin B